Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi's Sarcoma and Lymphatic Drainage by SPECT/CT

Inclusion Criteria

• •1. The subject has provided written informed consent with Health Insurance Portability and Accountability Act (HIPAA) authorization before the initiation of any study-related procedures.
• •2. The subject is at least 18 years of age at the time of consent.
• •3. The subject has an Eastern Cooperative Oncology Group (ECOG) performance status of Grade 0 to 2.
• •4. The subject has a KS stage of T(0), I(0), S(0).
• •5. The subject has a marker lesion with a confirmed diagnosis of KS (CD 206-expressing cutaneous KS) via punch biopsy. The location of the marker KS lesion will be limited to locations on the extremities: from the shoulder to the metacarpal region or from the groin to the metatarsal region.
• •6. The subject has a marker KS lesion that is ≥ 1cm in diameter.